# Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

> **NCT04323098** · PHASE3 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 22 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** valoctocogene roxaparvovec

## Key facts

- **NCT ID:** NCT04323098
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-08
- **Primary completion:** 2023-01-27
- **Final completion:** 2025-05-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323098, "Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04323098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*